Skip to main content

Table 3 Hazard ratios and 95% CI resulted from Cox proportional hazard regression modeling for hospitalized Covid-19 cases diagnosed two weeks after the second injection in study groups

From: Safety and efficacy of the FAKHRAVAC compared with BBIBP-Corv2 against SARS-CoV-2 in adults: a non-inferiority multi-center trial

Study arms

Totala

Vaccine groups

BBIBP-Corv2

Fakhravac

Person time, days

360,705

2,119,878

Number of events

8

11

Incidencee (95% CI)

0.22 (0.11,0.44)

0.05 (0.03,0.09)

Unadjusted HR (95% CI)

Ref

0.23 (0.09, 0.58)

Adjusted HRb (95% CI)

Ref

0.23 (0.09, 0.57)

Adjusted HRc (95% CI)

Ref

0.24 (0.1, 0.6)

Adjusted HRd (95% CI)

Ref

0.34 (0.13, 0.87)

  1. aResults from stratified cox proportional hazard regression, combining random and non-random arms
  2. bAdjusted for age, sex, and education
  3. cAdjusted for age, sex, education, and calendar week of the 1st injection
  4. dAdjusted for age, sex, education, calendar week of the 1st injection, and history of covid-19
  5. eIncidence per 1000
Back to article page

Virology Journal

ISSN: 1743-422X